Donald Baumstein, MD
Nephrology · New York, NYNPI 1902974447
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,600 of the $4,940 with a category attached, or 72.9%. Travere Therapeutics, Inc. accounts for 87.3% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $4,382 and has fallen 97.2% since, to $123 in 2025.
Across 26 payments — averaging $189.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$4K
- Sanofi$141
- Amgen$108
- Mallinckrodt Enterprises LLC$75
- Ceribell, Inc.$60
- Kestra Medical Technology Services, Inc.$46
- plus $196 from 8 others
What the payments were for
- Consulting fees$3,60073%
- Travel & lodging$4419%
- Food & beverage$82417%
- Education$752%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 8 | $4,314 |
| Sanofi | 2 | $141 |
| Amgen | 4 | $108 |
| Mallinckrodt Enterprises LLC | 1 | $75 |
| Ceribell, Inc. | 1 | $60 |
| Kestra Medical Technology Services, Inc. | 1 | $46 |
| AstraZeneca | 2 | $42 |
| Ardelyx, Inc. | 1 | $34 |
| Aurinia Pharma U.S., Inc. | 1 | $28 |
| Vifor Pharma, Inc. | 1 | $25 |
| Pfizer | 1 | $18 |
| Merck | 1 | $16 |
| Rockwell Medical, Inc. | 1 | $16 |
| GSK | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FABRAZYME$123
How this compares
$4,940 in reported general payments places this provider in the 80th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in New York
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Steven CocaNew York$445K
- Jai RadhakrishnanNew York$369K
- Girish NadkarniNew York$281K
- James ChevalierNew York$202K
- David CharytanNew York$164K
- Kirk CampbellNew York$152K
- Andrew BombackNew York$106K
- Alan PerlmanNew York$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.